US appeals court affirms invalidity of Yasmin patent
07 August 2009
Nancy Faigen
A US appeals court has upheld a lower court ruling that a key US patent on
Bayer Schering Pharma's oral contraceptive Yasmin (drospirenone plus ethinylestradiol) is invalid.
The US Appeals Court for the Federal Circuit, in a two to one ruling, said that the trial judge was correct to rule that...
Please Login to read the full article.
07 August 2009
Nancy Faigen
The US Appeals Court for the Federal Circuit, in a two to one ruling, said that the trial judge was correct to rule that...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pfizer's 'non obvious' Viagra patents good until 2019 to fend off Teva in US
- US Capitol Capsule: Supreme Court to weigh generic drug liability, patent burden-of-proof standards
- Lupin set for first launch in US generic oral contraceptive market
- US Capitol Capsule: Patent reform done, but will it create jobs?
COMMENT
Other Informa Comment
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
